Journal article
Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).
Abstract
1033
Background: MA.32 investigates effects of Metformin vs. Placebo, in addition to standard care, on invasive disease free survival and other outcomes. Metformin may improve obesity and metabolic factors [insulin, glucose, leptin, C-reactive protein (CRP)] that have been associated with poor BC outcomes. Maintaining blinding of investigators to outcomes, we conducted a planned, DSMB approved, analysis of the effect of …
Authors
Goodwin PJ; Parulekar W; Gelmon KA; Shepherd LE; Ligibel JA; Hershman DL; Rastogi P; Mayer IA; Hobday TJ; Lemieux J
Journal
Journal of Clinical Oncology, Vol. 31, No. 15_suppl, pp. 1033–1033
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2013
DOI
10.1200/jco.2013.31.15_suppl.1033
ISSN
0732-183X